Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 6/20 | 0.41 |
| ▸ | RARG | P13631 | 6/20 | 0.41 |
| ▸ | RARA | P10276 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736575 | 0.88 | SSTR5 (0.50) | AKR1B1SSTR5RARBRARGRARA | |
| SCHEMBL13668278 | 0.88 | KDM4E (0.43) | AKR1B1KDM4ERARBRARGRARA | |
| SCHEMBL8865292 | 0.82 | AKR1B1 (0.41) | AKR1B1KDM4ESSTR5RARBRARG | |
| SCHEMBL4516578 | 0.80 | CA12 (0.46) | AKR1B1KDM4ESSTR5RARBRARA | |
| Terephthalic Acid SCHEMBL9872879 | 0.80 | SSTR5 (0.49) | AKR1B1SSTR5RARBRARGRARA | |
| SCHEMBL9076000 | 0.79 | RARB (0.71) | KDM4ERARBRARGRARANPC1 | |
| SCHEMBL9076001 | 0.79 | RARB (0.71) | KDM4ERARBRARGRARANPC1 | |
| SCHEMBL9076004 | 0.79 | RARB (0.71) | KDM4ERARBRARGRARANPC1 | |
| SCHEMBL3547915 | 0.78 | RARB (0.63) | AKR1B1KDM4ERARBRARGRARA | |
| SCHEMBL9850145 | 0.77 | SSTR5 (0.46) | SSTR5RARBRARGRARARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351737-B2 | 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity | ALLERGAN, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1704139-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS | Allergan, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1280757-B1 | NEW GAMMA SELECTIVE RETINOIDS | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005066116-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RARϜ RETINOID RECEPTORS | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-1992006084-A1 | CHROMANS AND THIOCHROMANS WITH RETINOID-LIKE ACTIVITY | ALLERGAN, INC. (US) | 1992-04-16 | — | — | WO | disclosed |
| US-5053523-A | Chemical intermediate for compounds having retinoic acid-like activity | ALLERGAN, INC. (US) | 1991-10-01 | — | — | US | disclosed |
| US-5045551-A | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0435681-A1 | Chroman esters of phenols and benzoic acids having retinoid-like activity | ALLERGAN, INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| US-5023341-A | Acetylene thiochroman | ALLERGAN, INC. (US) | 1991-06-11 | — | — | US | disclosed |
| US-5006550-A | Skin disorder, arthritis, wound healing agents, dry eye syndrome | ALLERGAN, INC. (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0419130-A2 | Acetylenes disubstituted with a heteroaromatic group and A 2-substituted chromanyl, thiochromanyl or 1,2,3,4- tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0419132-A2 | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0419131-A2 | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| US-4980369-A | ANTIARTHRITIC AGENTS, SKIN DISORDERS, ANTIULCER AGENTS, WOUND HEALING AGENTS | ALLERGAN, INC. (US) | 1990-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | AKR1B1 198/4885KDM4E 3446/4885SSTR5 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.